{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T01:42:02Z","timestamp":1789609322180,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T00:00:00Z","timestamp":1650412800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Background:<\/jats:bold> Combining a fraction of exhaled nitric oxide (FeNO) and blood eosinophil count (B-EOS) may be a useful strategy for administration of biologics such as anti-IgE or anti-IL-5 to patients with type 2 inflammatory-predominant severe asthma and is important to be elucidated considering the increasing use of biologics.<\/jats:p><jats:p><jats:bold>Methods:<\/jats:bold> This cross-sectional study analyzed the clinical data from 114 adult patients with severe asthma, who were treated at Saitama Medical University Hospital. The eligible patients were stratified into four subgroups defined by thresholds of FeNO and blood eosinophil (B-EOS) counts to detect sputum eosinophilia, using the receiver operating characteristic curve analysis. A total of 75 patients with optimal samples were stratified into four subtypes defined by thresholds of sputum eosinophilia and neutrophilia. Clinical characteristics, pattern of biologics, and distribution of sputum subtypes were analyzed in the stratified subclasses according to the FeNO and B-EOS thresholds. The asthma exacerbation (AE)-free time of the FeNO\/B-EOS subgroups and any biologics treatment including anti-IgE or anti-IL-5 use were examined using the Kaplan\u2013Meier method. The hazard ratios (HRs) for AE-free time were examined using the Cox proportional hazard model.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> The optimal cutoff values for prediction of sputum eosinophilia were defined as \u22652.7% wherein for FeNO as \u226527\u00a0ppb and B-EOS as \u2265265\/\u00b5L were considered. The high-FeNO subgroups showed significant high total IgE, compared with the low FeNO. The high-FeNO\/high-B-EOS and the high-FeNO\/low-B-EOS subgroups showed the largest prevalence of mepolizumab and benralizumab use among the other FeNO\/B-EOS, respectively. The high-FeNO\/low-B-EOS showed the largest frequency of AEs, high HR, and the shortest AE-free time, among the other FeNO\/B-EOS. The sputum eosinophil-predominant subtype was the great majority in the high FeNO\/high B-EOS. A diverse distribution of sputum leukocyte-predominant subtype was observed in the other FeNO\/B-EOS. The subsequent AE-free time and its HR were comparable among the biologics use groups.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> The strategy of classifying severe asthma based on the combination of FeNO and B-EOS proposes particular refractory type 2 severe asthma and underlying airway inflammation as a feasible trait for optimal biologics use.<\/jats:p>","DOI":"10.3389\/fphar.2022.836635","type":"journal-article","created":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:09:50Z","timestamp":1650431390000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":11,"title":["Treatment Resistance in Severe Asthma Patients With a Combination of High Fraction of Exhaled Nitric Oxide and Low Blood Eosinophil Counts"],"prefix":"10.3389","volume":"13","author":[{"given":"Yuki","family":"Hoshino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Soma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshitaka","family":"Uchida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Shiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuyuki","family":"Nakagome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Nagata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,4,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1111\/all.14221","article-title":"Efficacy and Safety of Treatment with Biologicals (Benralizumab, Dupilumab, Mepolizumab, Omalizumab and Reslizumab) for Severe Eosinophilic Asthma. A Systematic Review for the EAACI Guidelines - Recommendations on the Use of Biologicals in Severe Asthma","volume":"75","author":"Agache","year":"2020","journal-title":"Allergy"},{"key":"B2","doi-asserted-by":"publisher","first-page":"912","DOI":"10.1164\/rccm.200406-710ST","article-title":"ATS\/ERS Recommendations for Standardized Procedures for the Online and Offline Measurement of Exhaled Lower Respiratory Nitric Oxide and Nasal Nitric Oxide, 2005","volume":"171","year":"2005","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1164\/ajrccm.161.2.9903097","article-title":"Induced Sputum Cell Counts in Healthy Adults","volume":"161","author":"Belda","year":"2000","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1800936","DOI":"10.1183\/13993003.00936-2018","article-title":"Baseline Patient Factors Impact on the Clinical Efficacy of Benralizumab for Severe Asthma","volume":"52","author":"Bleecker","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B5","doi-asserted-by":"publisher","first-page":"2702","DOI":"10.1016\/j.jaip.2021.01.011","article-title":"Real-World Effectiveness of Omalizumab in Severe Allergic Asthma: A Meta-Analysis of Observational Studies","volume":"9","author":"Bousquet","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B6","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1016\/j.jaip.2021.10.059","article-title":"Effective Management of Severe Asthma with Biologic Medications in Adult Patients: A Literature Review and International Expert Opinion","volume":"10","author":"Buhl","year":"2022","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1165","DOI":"10.1016\/S2213-2600(21)00124-7","article-title":"Baseline FeNO as a Prognostic Biomarker for Subsequent Severe Asthma Exacerbations in Patients with Uncontrolled, Moderate-To-Severe Asthma Receiving Placebo in the LIBERTY ASTHMA QUEST Study: a post-hoc Analysis","volume":"9","author":"Busse","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B8","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab Effectiveness by Biomarker Status in Patients with Asthma: Evidence from PROSPERO, A Prospective Real-World Study","volume":"7","author":"Casale","year":"2019","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B9","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1111\/j.1365-2222.2008.02969.x","article-title":"IL-13 Induced Increases in Nitrite Levels Are Primarily Driven by Increases in Inducible Nitric Oxide Synthase as Compared with Effects on Arginases in Human Primary Bronchial Epithelial Cells","volume":"38","author":"Chibana","year":"2008","journal-title":"Clin. Exp. Allergy"},{"key":"B10","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS Guidelines on Definition, Evaluation and Treatment of Severe Asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur. Respir. J."},{"key":"B12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1164\/rccm.201602-0419OC","article-title":"Inflammatory and Comorbid Features of Patients with Severe Asthma and Frequent Exacerbations","volume":"195","author":"Denlinger","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1164\/rccm.200905-0695OC","article-title":"Use of Exhaled Nitric Oxide Measurement to Identify a Reactive, At-Risk Phenotype Among Patients with Asthma","volume":"181","author":"Dweik","year":"2010","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1016\/j.jaip.2020.10.010","article-title":"Long-Term Therapy Response to Anti-IL-5 Biologics in Severe Asthma-A Real-Life Evaluation","volume":"9","author":"Eger","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1470","DOI":"10.1164\/ajrccm.163.6.9901105","article-title":"Safety and Reproducibility of Sputum Induction in Asthmatic Subjects in a Multicenter Study","volume":"163","author":"Fahy","year":"2001","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"CD010834","DOI":"10.1002\/14651858.CD010834.pub3","article-title":"Anti-IL5 Therapies for Asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"B18","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.jaci.2018.12.1020","article-title":"A Sputum 6-gene Signature Predicts Future Exacerbations of Poorly Controlled Asthma","volume":"144","author":"Fricker","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"B19","article-title":"Global Strategy for Asthma Management and Prevention","year":"2021"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2021.02.016","article-title":"The Basic Immunology of Asthma","volume":"184","author":"Hammad","year":"2021","journal-title":"Cell"},{"key":"B21","doi-asserted-by":"publisher","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the Effects of Omalizumab in Allergic Asthma: an Analysis of Biomarkers in the EXTRA Study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1902420","DOI":"10.1183\/13993003.02420-2019","article-title":"Mepolizumab Effectiveness and Identification of Super-responders in Severe Asthma","volume":"55","author":"Harvey","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1164\/rccm.202009-3713OC","article-title":"Mixed Sputum Granulocyte Longitudinal Impact on Lung Function in the Severe Asthma Research Program","volume":"203","author":"Hastie","year":"2021","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B24","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.jaci.2015.11.020","article-title":"Multidimensional Endotyping in Patients with Severe Asthma Reveals Inflammatory Heterogeneity in Matrix Metalloproteinases and Chitinase 3-like Protein 1","volume":"138","author":"Hinks","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1900588","DOI":"10.1183\/13993003.00588-2019","article-title":"Management of Severe Asthma: a European Respiratory Society\/American Thoracic Society Guideline","volume":"55","author":"Holguin","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B26","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1136\/thoraxjnl-2020-215168","article-title":"Characterisation of Patients with Severe Asthma in the UK Severe Asthma Registry in the Biologic Era","volume":"76","author":"Jackson","year":"2021","journal-title":"Thorax"},{"key":"B27","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.chest.2020.03.042","article-title":"Real-World Effectiveness and the Characteristics of a \"Super-responder\" to Mepolizumab in Severe Eosinophilic Asthma","volume":"158","author":"Kavanagh","year":"2020","journal-title":"Chest"},{"key":"B28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.chest.2020.08.2083","article-title":"Real-World Effectiveness of Benralizumab in Severe Eosinophilic Asthma","volume":"159","author":"Kavanagh","year":"2021","journal-title":"Chest"},{"key":"B29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1016\/S2213-2600(15)00050-8","article-title":"Diagnostic Accuracy of Minimally Invasive Markers for Detection of Airway Eosinophilia in Asthma: a Systematic Review and Meta-Analysis","volume":"3","author":"Korevaar","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"2100413","DOI":"10.1183\/13993003.00413-2021","article-title":"Patient Characteristics, Biomarkers and Exacerbation Risk in Severe, Uncontrolled Asthma","volume":"58","author":"Kraft","year":"2021","journal-title":"Eur. Respir. J."},{"key":"B31","doi-asserted-by":"publisher","first-page":"113978","DOI":"10.1016\/j.bcp.2020.113978","article-title":"Prediction of Response to Biological Treatment with Monoclonal Antibodies in Severe Asthma","volume":"179","author":"Kroes","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"B32","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1016\/j.jaci.2013.06.007","article-title":"Exhaled Nitric Oxide Levels and Blood Eosinophil Counts Independently Associate with Wheeze and Asthma Events in National Health and Nutrition Examination Survey Subjects","volume":"132","author":"Malinovschi","year":"2013","journal-title":"J. Allergy Clin. Immunol."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/j.jaci.2016.01.044","article-title":"Simultaneously Increased Fraction of Exhaled Nitric Oxide Levels and Blood Eosinophil Counts Relate to Increased Asthma Morbidity","volume":"138","author":"Malinovschi","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1016\/j.resinv.2020.05.006","article-title":"An Official JRS Statement: The Principles of Fractional Exhaled Nitric Oxide (FeNO) Measurement and Interpretation of the Results in Clinical Practice","volume":"59","author":"Matsunaga","year":"2021","journal-title":"Respir. Investig."},{"key":"B35","doi-asserted-by":"publisher","first-page":"1174","DOI":"10.1016\/S2213-2600(21)00004-7","article-title":"The Inflammatory Profile of Exacerbations in Patients with Severe Refractory Eosinophilic Asthma Receiving Mepolizumab (The MEX Study): a Prospective Observational Study","volume":"9","author":"McDowell","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"B36","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of Spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur. Respir. J."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1016\/j.jaci.2013.10.011","article-title":"Sputum Neutrophil Counts Are Associated with More Severe Asthma Phenotypes Using Cluster Analysis","volume":"133","author":"Moore","year":"2014","journal-title":"J. Allergy Clin. Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1016\/j.alit.2019.06.003","article-title":"Prevalence, Disease burden, and Treatment Reality of Patients with Severe, Uncontrolled Asthma in Japan","volume":"69","author":"Nagase","year":"2020","journal-title":"Allergol. Int."},{"key":"B39","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/j.alit.2020.08.001","article-title":"Japanese Guidelines for Adult Asthma 2020","volume":"69","author":"Nakamura","year":"2020","journal-title":"Allergol. Int."},{"key":"B40","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/iid3.166","article-title":"A Trial of Oral Corticosteroids for Persistent Systemic and Airway Inflammation in Severe Asthma","volume":"5","author":"Oishi","year":"2017","journal-title":"Immun. Inflamm. Dis."},{"key":"B41","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/S2213-2600(16)30031-5","article-title":"Severe Eosinophilic Asthma Treated with Mepolizumab Stratified by Baseline Eosinophil Thresholds: a Secondary Analysis of the DREAM and MENSA Studies","volume":"4","author":"Ortega","year":"2016","journal-title":"Lancet Respir. Med."},{"key":"B42","doi-asserted-by":"publisher","first-page":"3s","DOI":"10.1183\/09031936.02.00000302","article-title":"Sputum Induction","volume":"37","author":"Paggiaro","year":"2002","journal-title":"Eur. Respir. J. Suppl."},{"key":"B43","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1164\/rccm.201807-1291OC","article-title":"A Transcriptomic Method to Determine Airway Immune Dysfunction in T2-High and T2-Low Asthma","volume":"199","author":"Peters","year":"2019","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B44","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/S2213-2600(15)00367-7","article-title":"Blood Eosinophil Count and Prospective Annual Asthma Disease burden: a UK Cohort Study","volume":"3","author":"Price","year":"2015","journal-title":"Lancet Respir. Med."},{"key":"B45","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1007\/s00408-019-00310-8","article-title":"Effect of Anti-IL5, Anti-IL5R, Anti-IL13 Therapy on Asthma Exacerbations: A Network Meta-Analysis","volume":"198","author":"Ramonell","year":"2020","journal-title":"Lung"},{"key":"B46","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1164\/rccm.200801-060ST","article-title":"An Official American Thoracic Society\/European Respiratory Society Statement: Asthma Control and Exacerbations: Standardizing Endpoints for Clinical Asthma Trials and Clinical Practice","volume":"180","author":"Reddel","year":"2009","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"B47","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1016\/j.jaci.2017.02.045","article-title":"Sputum Transcriptomics Reveal Upregulation of IL-1 Receptor Family Members in Patients with Severe Asthma","volume":"141","author":"Rossios","year":"2018","journal-title":"J. Allergy Clin. Immunol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"410","DOI":"10.1016\/j.chest.2017.01.021","article-title":"Hematopoietic Processes in Eosinophilic Asthma","volume":"152","author":"Salter","year":"2017","journal-title":"Chest"},{"key":"B49","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1016\/j.rmed.2014.10.007","article-title":"Heterogeneity of Phenotypes in Severe Asthmatics. The Belgian Severe Asthma Registry (BSAR)","volume":"108","author":"Schleich","year":"2014","journal-title":"Respir. Med."},{"key":"B50","doi-asserted-by":"publisher","first-page":"S3","DOI":"10.1016\/j.alit.2018.04.003","article-title":"Implication of Fraction of Exhaled Nitric Oxide and Blood Eosinophil Count in Severe Asthma","author":"Soma","year":"2018","journal-title":"Allergol. Int."},{"key":"B52","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s40733-016-0021-y","article-title":"CXC Chemokine Superfamily Induced by Interferon-\u03b3 in Asthma: a Cross-Sectional Observational Study","volume":"2","author":"Takaku","year":"2016","journal-title":"Asthma Res. Pract."},{"key":"B53","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.anai.2020.06.017","article-title":"Spontaneous Sputum Discriminates Inflammatory Phenotypes in Patients with Asthma","volume":"126","author":"Tanaka","year":"2021","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B54","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/j.anai.2019.04.008","article-title":"Implications of Prostaglandin D2 and Leukotrienes in Exhaled Breath Condensates of Asthma","volume":"123","author":"Uchida","year":"2019","journal-title":"Ann. Allergy Asthma Immunol."},{"key":"B56","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02770903.2021.1963769","article-title":"Blood Eosinophil Count and FeNO to Predict Benralizumab Effectiveness in Real-Life Severe Asthma Patients","volume":"17","author":"Watanabe","year":"2021","journal-title":"J. Asthma"},{"key":"B57","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/j.jaip.2014.06.005","article-title":"High Blood Eosinophil Count Is a Risk Factor for Future Asthma Exacerbations in Adult Persistent Asthma","volume":"2","author":"Zeiger","year":"2014","journal-title":"J. Allergy Clin. Immunol. Pract."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.836635\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,20]],"date-time":"2022-04-20T05:09:53Z","timestamp":1650431393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2022.836635\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,20]]},"references-count":53,"alternative-id":["10.3389\/fphar.2022.836635"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2022.836635","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,20]]},"article-number":"836635"}}